Hyperspectral Imaging Signatures Detect Amyloidopathy in Alzheimer’s Mouse Retina Well before Onset of Cognitive Decline
Open Access
- 26 November 2014
- journal article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 6 (2), 306-315
- https://doi.org/10.1021/cn500242z
Abstract
Amyloidopathic disorders such as Alzheimer's disease present symptomology years after the entrenchment of amyloidogenic imbalance. The pathologic α-helix → β-strand conversion of amyloid β(1-42) and amyloid β(1-40) peptides causes neuronal death in the vicinity. Symptomology often presents only after significant neurodegeneration. This thus warrants early detection of amyloidopathy in Alzheimer's disease. Nonexistent modalities for direct identification and quantitation of soluble amyloid aggregates or (proto)fibrils forced us to undertake the development of a spectrophotometric technique to support ongoing drug design. Key requirements were independence from the need for extraneous staining, unambiguous amyloid aggregate detection, and minimal influence of interpretative errors. A Cytoviva instrument pivotal to this study captures scattering of light of visible-near-infrared (VNIR, 400-1000 nm) wavelengths within each pixel of the microscopic view field. We thus assembled a scattering intensity pattern database that provided "signatures" of amyloid aggregates. Comparison of unknown samples against this database enabled direct detection of amyloid aggregates. The technique was found useful for monitoring retinal and brain amyloidopathy in an ongoing preclinical anti-AD study, attesting to the technique's sensitivity and specificity. Interestingly, the technique was found applicable not just to excised brain tissue but also to isolated mouse retina. With the retina being heralded widely as a (diagnostic) extension of the CNS and retinal amyloidopathy occurring well before that in the brain, this development raises a possibility for the first direct retinal imaging diagnosis of early asymptomatic Alzheimer's disease.Keywords
Funding Information
- Center for Drug Design Endowment
This publication has 38 references indexed in Scilit:
- The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegenerationBiochemical Journal, 2013
- Brain amyloid-β oligomers in ageing and Alzheimer’s diseaseBrain, 2013
- Distinguishing crystal-like amyloid fibrils and glass-like amorphous aggregates from their kinetics of formationProceedings of the National Academy of Sciences of the United States of America, 2012
- Prion protein misfolding and diseaseCurrent Opinion in Structural Biology, 2009
- Molecular and cellular aspects of protein misfolding and diseaseThe FASEB Journal, 2008
- Quality control of protein folding in extracellular spaceEMBO Reports, 2005
- Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseasesNature, 2004
- Folding proteins in fatal waysNature, 2003
- Assembly of Amyloid Protofibrils via Critical Oligomers—A Novel Pathway of Amyloid FormationJournal of Molecular Biology, 2003
- Amyloid β-Protein FibrillogenesisJournal of Biological Chemistry, 1997